A Phase III, Randomized, Open-lable, Multi Center Study of Sintilimab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Curative Hepatic Resection
Latest Information Update: 28 Dec 2020
At a glance
- Drugs Bevacizumab (Primary) ; Sintilimab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms DaDaLi
- 28 Dec 2020 New trial record